34 results about "Spleen Tissue" patented technology

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The present invention provides lipid nanoparticles for delivering nucleic acid to spleen tissue that can improve the efficiency of nucleic acid delivery to spleen tissue cells, and a method for delivering nucleic acid to spleen tissue by using same. A lipid nanoparticle for use in delivering a nucleic acid to a spleen tissue, including(A) an ionic lipid represented by the formula (1),(B) an anionic phospholipid or a compound represented by the formula (2),(C) cholesterol, and(D) a dimyristoylglycerol PEG represented by the formula:(definitions of symbols in the formula are as described in the specification), and a method for delivering a nucleic acid to a spleen tissue by using same.

The present application provides a kind of bioactive seventeen peptides and its application, belong to bioactive peptide technical field, the amino acid sequence of the seventeen peptides is as shown in SEQ ID NO.1;Seventeen peptides provided by the present application can significantly reduce immune damage, improve immune organ index, reduce spleen tissue damage, can significantly promote the secretion level of immunoglobulin and cytokine in blood;The polypeptide has immunoregulation, can improve immunity, can be used for preparing the product of enhancing immunity.

According to the invention, GWAS analysis is carried out on immune traits of Qingyuan partridge chicken infected with ALV-J, and SNP molecular markers related to immune traits such as spleen tissue index, pancreatic tissue index, IL-6 content in blood, IFN-beta content in blood and cloaca virus positive degree are screened and obtained; the SNP molecular markers can be applied to disease-resistant molecular marker assisted breeding of Qingyuan partridge chickens. Through molecular marker-assisted breeding, the spleen tissue index, the pancreatic tissue index, the IL-6 content and the IFN-beta content in blood of the Qingyuan partridge chicken can be increased, especially the IL-6 content and the IFN-beta content in the blood infected with ALV-J can be increased, the ALV-J infection resistance of the chicken is improved, and the immunity of the chicken is improved. Meanwhile, breeding is assisted through the molecular marker, the cloaca virus positive degree of the chickens infected with ALV-J can be reduced, the diseases infected with ALV-J and the ALV-J infection resisting capacity are relieved, and the immunity of the chickens is improved. Therefore, the medicine use cost of the chicken farm is reduced, the economic performance of the chicken farm is improved, and healthy breeding is promoted.

The present application provides a kind of PRMT5 inhibitor, PRMT5 inhibitor includes: recombinant adeno-associated virus vector AAV-shPrmt5 and GSK3326595;Recombinant adeno-associated virus vector AAV-shPrmt5 includes the shRNA of targeting PRMT5, the nucleotide sequence of shRNA is as shown in SEQ ID No:1.The present application also provides the application of the above-mentioned PRMT5 inhibitor in the preparation of drug for improving primary biliary cholangitis, PRMT5 inhibitor is all PRMT5 gene / protein as target point, by inhibiting the expression of PRMT5 gene / protein, reduce liver tissue and spleen tissue Tfh cell and GC B cell, serum autoantibody and transaminase level, can effectively delay the disease progression of primary biliary cholangitis.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating leucopenia as well as a preparation method and application thereof. The composition is prepared from fructus momordicae, fructus ligustri lucidi, ginseng leaves and roses as raw materials through extraction. Experiments show that the composition can significantly increase the number and vitality of leukocytes so as to play multiple roles in increasing leukocytes, improving pathological injury of spleen tissues and enhancing immunity, and the effects are significantly superior to those of a formula-lacking control or a formula-replacing control. Therefore, all the components in the composition cooperate with one another and take effect synergistically, and are indispensable.

This invention belongs to the field of animal feed technology and discloses the application of glucuronolactone in the preparation of feed that alleviates spleen damage caused by the combined effects of PRRSV and DON. This invention discovers that glucuronolactone can effectively alleviate spleen damage in piglets caused by co-exposure to PRRSV and DON. It exerts its protective effect by activating the Nrf2 antioxidant signaling pathway, improving spleen tissue structure, alleviating oxidative stress, inhibiting inflammatory responses, and inhibiting apoptosis. This invention also provides a feed containing the aforementioned effective amount of glucuronolactone, with the basic feed tailored to the nutritional needs of piglets. This invention fills the technological gap in effective intervention methods for spleen damage under PRRSV and DON co-exposure. The glucuronolactone addition process is simple, the effect is significant, and it is suitable for large-scale feed production. It can effectively solve the problem of immunosuppression in pig herds caused by the combined harm of PRRSV and DON in the pig industry, and has important practical value.

The present invention provides a spleen removal device that can automatically decompose tissue during minimally invasive splenectomy, comprising an inner cylinder, the outer cylinder being rotatably connected to the inner cylinder, a support plate being installed at the end of the outer cylinder, a mounting rod being installed inside the inner cylinder, a connecting platform being slidably connected to the surface of the mounting rod, a resection head being provided inside the inner cylinder, a connecting platform being rotatably connected to the end of the connecting platform, and a connecting block being rotatably connected to the end of the connecting rod. The resection head, connecting rod, first pull rod, limit plate, and offset adjustment mechanism are provided so that the resection head can adjust its own angle. When resecting a smaller necrotic area on the surface of the spleen, the resection head is tilted at different angles according to the size of the necrotic area. At this time, the contact area between the resection head and the spleen will change according to the tilt angle. By adjusting the tilt angle of the resection head, the doctor can more accurately control the resection range, ensuring that only necrotic spleen tissue is removed while preserving as much healthy spleen as possible.

The invention provides application of low-intensity focused ultrasound in preparation of a noninvasive asthma treatment product, and belongs to the technical field of asthma treatment. The low-intensity focused ultrasound treats the asthma by regulating and controlling the activity of the spleen nerves, the low-intensity focused ultrasound has high targeting, accuracy and durability on the asthma, and the spleen histological injury or dysfunction of adjacent organs (such as pancreas and kidneys) is not observed, so that the effectiveness and safety of the technology are proved.

The invention provides a novel application of a cordate houttuynia extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a mouse infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected mouse liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the Houttuynia cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The potential application of the herba houttuyniae extract in the aspect of resisting salmonella toxicity is disclosed for the first time, and a development strategy and a technical basis of a T3SS inhibitor derived from a natural product are provided.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus pentosus S115-6 and application of a product of the lactobacillus pentosus S115-6 in improving immunity. The lactobacillus pentosus is S115-6, and the preservation number of the lactobacillus pentosus is GDMCC No: 65464. The strain has good acid resistance, cholate resistance and gastrointestinal fluid tolerance, and has strong adhesion to intestinal epithelial cells; the traditional Chinese medicine composition can relieve atrophy of immune organs, promote structural recovery of the immune organs, remarkably improve spleen tissue damage in an immunosuppression state and promote repair of the immune organs; the secretion of immune globulins IgA, IgG and IgM can be promoted, the levels of IL-6 and IFN-alpha in serum of mice can be reduced, and the levels of IL-2 and IFN-gamma cell factors can be increased.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.

The invention discloses an application of aspergillus versicolor exopolysaccharide AVP214-1 in preparation of a medicine for resisting Singapore grouper iridovirus. It is found that in an in-vitro experiment, the AVP214-1 can significantly reduce the cytopathy degree induced by Singapore grouper iridovirus (SGIV), and the transcriptional level and the protein level of viral genes MCP and VP19 are reduced; furthermore, the AVP214-1 is applied to grouper in-vivo experiments, the AVP214-1 also has a good anti-SGIV effect, and a tissue slice result shows that an AVP214-1 treatment group relieves liver and spleen histopathologic changes caused by SGIV infection, and can significantly reduce the transcriptional level of viral genes MCP, VP19 and ICP18. The research provided by the invention has an extremely important significance in preventing or treating the fish iridovirus disease caused by the iridovirus of Singapore grouper by utilizing the AVP214-1.

The invention relates to the technical field of polypeptide preparation, and discloses a spleen extract preparation method, which comprises: carrying out pretreatment, homogenization, freeze thawing crushing, precipitation separation and ultrafiltration on a mammal spleen tissue to obtain a spleen polypeptide extract; coupling the spleen polypeptide extract with ADC through a chemical coupling bridge to form a targeting compound; preparing an antioxidant-basic amino acid compound; mixing the coupling compound with a wall material solution containing a functional filling agent and an antioxidant-alkaline amino acid compound, and carrying out microencapsulation embedding; carrying out freeze drying on the microcapsules; and spraying a chitosan-sodium carboxymethyl cellulose polyelectrolyte compound on the surface of the freeze-dried microcapsule to carry out hydrophilic modification. The antioxidant-basic amino acid compound is used for blocking intermolecular chemical crosslinking, the cyclodextrin inclusion effect is used for preventing aggregation, and the polysaccharide composite hydrophilic layer is used for providing environmental tolerance, so that the chemical crosslinking rate of the product is reduced by 80% or above, and the aggregation rate is reduced to 5% or below.

The invention discloses application of a xanthoceras sorbifolia extract in preparation of a medicine for preventing and / or treating electromagnetic radiation damage. Experiments show that the xanthoceras sorbifolia bunge flower extract can improve the weight loss of rats caused by microwave radiation; brain tissue structure change damage caused by microwave radiation is improved; the reduction of the learning and memory ability of the rats caused by microwave radiation is improved; the brain sea horse tissue amino acid neurotransmitter disorder caused by microwave radiation is improved; electroencephalogram alpha and beta wave abnormity caused by microwave radiation is improved; the sperm motility reduction caused by microwave radiation is improved; the rat serum sex hormone disorder caused by microwave radiation is improved; rat testicular tissue oxidative stress injury caused by microwave radiation is improved; the abnormal energy metabolism of testicular tissues caused by microwave radiation is improved; heart electrophysiological abnormality and heart tissue ultrastructure abnormality caused by microwave radiation are improved; the immune function decline caused by microwave radiation is improved; the influence of microwave radiation on the content of IL-2, 4 is improved; the influence of microwave radiation on the thymus and spleen tissue structure is improved.

The invention provides a novel application of a macleaya cordata extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a chick infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected chick liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the macleaya cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The invention discloses the potential application of the macleaya cordata extract in the aspect of resisting salmonella toxicity for the first time, and provides a development strategy and a technical basis of a T3SS inhibitor from a natural product.

Embodiments of the present application provide a spleen structure analysis method and device, electronic equipment and storage medium. The method comprises obtaining a spleen structure analysis request, the spleen structure analysis request comprising first single-cell sequencing data and first spatial transcriptome sequencing data of a spleen tissue to be analyzed; determining a plurality of first significantly expressed gene data corresponding to a plurality of cell types according to the first single-cell sequencing data, and determining a plurality of second significantly expressed gene data corresponding to a plurality of spleen partitions according to the first spatial transcriptome sequencing data; determining a first intersection between the second significantly expressed gene data of each spleen partition and the first significantly expressed gene data of each cell type, and constructing an input data set based on the first intersection; determining a spleen structure analysis result according to the similarity between the input data set and a reference data set, the reference data set being a data set corresponding to a spleen sample of a reference spleen structure. The method can improve the accuracy of spleen structure analysis.

This invention relates to the field of biomedical technology, and discloses a 6mA modified single-stranded DNA sequence that specifically binds to the MYH9 protein and its application in the treatment of sepsis; the single-stranded DNA sequence is specifically bound to the MYH9 protein. N 6 A single-stranded DNA sequence modified with 6mA-methyladenine (nucleotide sequence shown in SEQ ID NO:1) exhibits a specific adenine (A) methylation at a specific position, which allows it to be specifically recognized and bound by the MYH9 protein. The binding specificity was verified in vitro / in vivo using EMSA, biotin DNA pulldown WB assays, and MYH9-DNA IP assays. This 6mA-modified single-stranded DNA, by binding to the MYH9 protein, activates the downstream JAK1-STAT6 signaling pathway, promoting macrophage polarization towards the M2 phenotype, inhibiting excessive inflammatory responses, improving survival rates, reducing pathological damage to spleen tissue, and ameliorhythmic symptoms such as weight loss and hypothermia in septic mice, thereby exerting an anti-septic effect. This effectively addresses the clinical pain points of existing non-specific anti-inflammatory therapies and possesses significant potential for drug development.

The invention relates to the field of biological medicines, in particular to application of mogroside in preparation of medicines for treating and / or preventing leucopenia. The invention provides application of mogroside in preparation of a medicine for treating and / or preventing leucopenia. The invention provides a medicine for treating mogroside V and mogroside IIE, and the medicine can obviously increase the level of blood cells such as leukocytes, improve pathological damage of spleen tissues, activate hematopoietic cell lineage and cell cycle signal pathways in leucopenia, especially in the pathological process of rapid reduction of leukocytes in an immunosuppressive state after chemotherapy, so that the treatment effect of the medicine is improved. The aurora kinase B and transferrin receptor gene expression is activated, and the organism immunity is enhanced. Mogroside V and mogroside IIE have the advantages of definite curative effect, low treatment cost and small toxic and side effects when being used for treating leucopenia, and are very suitable for clinical popularization and application.

The present invention relates to a novel Pediococcus acidilactici WiKim0170 strain having immunity-enhancing efficacy and a composition for enhancing immunity, comprising same. In the present invention, it has been discovered that the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, significantly increases spleen NK cell activity and increases inflammatory mediator, immunoglobulin, and cytokine production amounts, thereby improving an immunosuppressive reaction. In addition, the Pediococcus acidilactici WiKim0170 strain has been confirmed to increase the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in spleen tissue and increase the phosphorylation levels of NF-κB and IκBα, thereby having an effect of mitigating decreased immunity. Thus, according to the present invention, the composition comprising the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, as an active ingredient is expected to be usefully employable as a pharmaceutical and functional food composition for enhancing immunity.

The invention discloses application of an exosome in preparation of a medicine for treating myocardial injury, and belongs to the technical field of medicines. The exosome is derived from spleen tissues. The exosome can target the heart, is effectively enriched in ischemic myocardium, can significantly improve myocardial cell energy metabolism by enriching mitochondrial oxidative phosphorylation pathway key proteins, and provides an efficient and high-specificity solution for damage treatment of myocardium.

The invention discloses a selenized codonopsis pilosula polysaccharide and Sijunzi decoction composition as well as a preparation method and application thereof. The composition is prepared from codonopsis pilosula, bighead atractylodes rhizome, poria cocos, liquorice and selenized codonopsis pilosula polysaccharide. Each 1000 mL of the liquid medicine contains 15-20 g of codonopsis pilosula, 10-15 g of bighead atractylodes rhizome, 10-15 g of poria cocos, 5-10 g of liquorice and 4-6 mg of selenized codonopsis pilosula polysaccharide. The polysaccharide content in the liquid medicine is not lower than 0.5%, and the selenium content is not lower than 0.05%. The preparation method comprises the following steps: decocting with water to extract codonopsis pilosula, bighead atractylodes rhizome, poria cocos and liquorice, and mixing with selenized codonopsis pilosula polysaccharide. The selenized codonopsis pilosula polysaccharide and sijunzi decoction composition disclosed by the invention is derived from natural traditional Chinese medicines, and has no toxic or side effect and no hidden danger of medicine residues; the prescription is refined, the quality is controllable, the dosage form is advanced, and administration is convenient; when the newcastle disease vaccine is singly used or matched with the newcastle disease vaccine to immunize chicks, the weight can be obviously increased, the serum antibody titer can be improved, the thymus organ index can be increased, the white marrow proportion of spleen tissues can be increased, the cellular immunity and humoral immunity can be obviously enhanced, and the immune response of the vaccine can be improved.

The invention discloses application of an NASH-HCC mouse model, and belongs to the technical field of drug evaluation. The NASH-HCC mouse model can be applied to screening and / or evaluation of drugs and / or equipment for treating and / or preventing liver diseases, the NASH-HCC mouse model is an inducible Cre mouse, the HRAS protein is specifically and highly expressed in the liver under the induction of an inducer, and the liver diseases are NAFLD, NASH or HCC. The model can comprehensively evaluate the curative effect of a drug treatment scheme through multiple aspects such as mouse liver weight, blood biochemical indexes, total ROS (reactive oxygen species) amount of liver and spleen tissues, immune cell change conditions and the like, and provides support and assistance for clinical application.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The invention provides an antibody-exosome, a preparation method thereof and application of the antibody-exosome in preparation of ricin detoxification drugs, and belongs to the technical field of drug delivery and intracellular therapy. The antibody-exosome disclosed by the invention comprises a milk-derived exosome (mExo) and a single-domain antibody V9E1 of an anti-ricin A chain; the amino acid sequence of the V9E1 is as shown in SEQ ID NO. 1. V9E1 is loaded into a milk exosome by using a saponin perforation method to obtain a V9E1 antibody-exosome, and the antibody-exosome shows reliable biological safety in both cells and animal bodies; the cell survival rate can be obviously improved in a Vero cell acute poisoning model; after mice are poisoned by ricin for 2 hours and 6 hours, the survival rate of the mice can be remarkably improved; through continuous administration, all mice injected with ricin with a complete lethal dose can survive, liver and spleen tissues can be protected, and the method has the potential of replacing a traditional ricin antibody therapy.

The invention discloses a hybrid snakehead spleen cell line as well as an establishment method and application thereof, and belongs to the technical field of fish cell culture. The hybrid snakehead spleen cell line provided by the invention is named as CAMSp and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202598. According to the application, the spleen tissue from the hybrid snakehead is subjected to cell culture, the culture conditions of the cells are preliminarily determined, the sensitivity of the cells to the hybrid snakehead rhabdovirus (HSHRV) is detected, and a material basis is provided for researching the pathogenesis of the HSHRV, a detection method, vaccine preparation, interaction with host cells, disease prevention and control and the like.

The invention discloses a verbena extract with an anti-radiation effect and a preparation method and application thereof.The preparation method comprises the specific steps that the overground part of verbena is taken, ethyl alcohol is added for heating reflux operation, and then the obtained mixed solution is filtered to obtain an extracting solution; the extraction process is repeated for 1-3 times, then extracting solutions obtained in multiple times are combined, concentration and drying treatment are carried out, and finally an extractum-like substance, namely the verbena extract, is obtained. The traditional Chinese medicine composition can effectively improve the morphology and pathological change of spleen tissues, significantly increase the counting level of peripheral blood leukocytes (WBC), neutrophils (NE) and lymphocytes (LY), and reduce the release of inflammatory factors such as tumor necrosis factor alpha (TNF-alpha), interleukin 17 (IL-17) and interleukin 6 (IL-6); in this way, the tissue damage degree caused by radiation can be practically reduced, and a potential effective intervention means is provided for treating radiation damage.

The application belongs to the technical field of biological genetic engineering, and relates to application of PRMT7 as a target point in preparation of a medicine for inhibiting proliferation of subgroup J avian leukemia virus, and application of a PRMT7 gene polymorphism site as a molecular marker for evaluating resistance of poultry to subgroup J avian leukemia virus. Research shows that PRMT7 is involved in immune regulation of a host to infection of subgroup J avian leukemia virus, and inhibition of PRMT7 expression can enhance activity of a type I interferon related path and reduce a virus replication level. Further, a plurality of nucleotide polymorphism sites in the PRMT7 gene are screened to obtain a significant correlation with an ALV-J related phenotype, and the related phenotype includes a pancreas tissue index, a spleen tissue index, a bursa of fabricius tissue index, an IL-6 level and an IFN alpha level. The application provides a new technical scheme for prevention and control of subgroup J avian leukemia virus, development of an antiviral target point and poultry disease resistance molecular breeding.

This invention provides a lipid compound and its applications, the results of which are shown in Formula I. The lipid compound provided by this invention can be used for targeted delivery of bioactive molecules to splenic T cells, particularly suitable for transporting negatively charged nucleic acid molecules, such as mRNA, providing a potential delivery strategy for in vivo specific gene editing of T cells. This invention also provides a bioactive substance delivery system comprising the lipid compound, which is loaded with bioactive substances. The bioactive substance delivery system of this invention, after intravenous administration, can efficiently target spleen tissue and selectively deliver active substances to T cells within the spleen, achieving efficient T cell transfection and immune activation. The delivery system of this invention has a simple synthesis process and strong structural tunability, and has broad application prospects in the fields of T cell immunotherapy and gene therapy.

The present invention provides an active polysaccharide from the genus Pteris serrata, a preparation method, and an application thereof. The polysaccharide comprises mannose, rhamnose, glucuronic acid, glucose, galactose, xylose, arabinose, and fucose in a molar ratio of (9.6-9.8): (8.5-8.7): (3.1-3.3): (37.0-37.2): (21.3-21.5): (4.4-4.6): (7.2-7.4): (5.8-6.0). The active polysaccharide prepared by the present invention can increase the phagocytic activity of RAW264.7 cells, increase the serum IgM level of immunosuppressed mice, improve the spleen tissue morphology of immunosuppressed mice, increase the organ index of immunosuppressed mice, and increase the proportion of T lymphocytes in the spleen of immunosuppressed mice, thereby significantly improving immunity.